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Abstract
Poor angiogenesis is a major road block for tissue repair. The regeneration of virtually all tissues is limited by angiogenesis,
given the diffusion of nutrients, oxygen, and waste products is limited to a few hundred micrometers. We postulated that
co-transplantation of hematopoietic and mesenchymal stem/progenitor cells improves angiogenesis of tissue repair and
hence the outcome of regeneration. In this study, we tested this hypothesis by using bone as a model whose regeneration
is impaired unless it is vascularized. Hematopoietic stem/progenitor cells (HSCs) and mesenchymal stem/progenitor cells
(MSCs) were isolated from each of three healthy human bone marrow samples and reconstituted in a porous scaffold. MSCs
were seeded in micropores of 3D calcium phosphate (CP) scaffolds, followed by infusion of gel-suspended CD34
+
hematopoietic cells. Co-transplantation of CD34
+ HSCs and CD34
2 MSCs in microporous CP scaffolds subcutaneously in the
dorsum of immunocompromized mice yielded vascularized tissue. The average vascular number of co-transplanted CD34
+
and MSC scaffolds was substantially greater than MSC transplantation alone. Human osteocalcin was expressed in the
micropores of CP scaffolds and was significantly increased upon co-transplantation of MSCs and CD34
+ cells. Human nuclear
staining revealed the engraftment of transplanted human cells in vascular endothelium upon co-transplantation of MSCs
and CD34
+ cells. Based on additional in vitro results of endothelial differentiation of CD34
+ cells by vascular endothelial
growth factor (VEGF), we adsorbed VEGF with co-transplanted CD34
+ and MSCs in the microporous CP scaffolds in vivo, and
discovered that vascular number and diameter further increased, likely owing to the promotion of endothelial
differentiation of CD34
+ cells by VEGF. Together, co-transplantation of hematopoietic and mesenchymal stem/progenitor
cells may improve the regeneration of vascular dependent tissues such as bone, adipose, muscle and dermal grafts, and
may have implications in the regeneration of internal organs.
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Introduction
Poor angiogenesis is a common and critical barrier in tissue
regeneration. Regenerating tissue over 100–200 mm exceeds the
capacity of nutrient supply and waste removal by diffusion, and thus
requires an intimate supply of vascular networks [1,2]. Previous
attempts in engineered angiogenesis have relied on the delivery of
angiogenic growth factors, transplantation of proangiogenic cells or
the fabrication of blood vessel analogs [3–6]. In a number of
meritorious studies, angiogenesis in scaffolding materials has been
induced by a number of angiogenic cytokines such as vascular
endothelial growth factor (VEGF), platelet derived growth factors
(PDGF), and basic fibroblast growth factor (bFGF) [7–14]. Despite
promising results, there are continuing concerns over the cost of
multiple cytokines and delivery, potential toxicity, and suboptimal
endothelial migration in large tissue grafts. The transplantation of
proangiogenic cells, such as endothelial cells or endothelial
progenitor cells, has led to the formation of blood vessels with
suboptimal life span [15]. Short of sustained survival of transplanted
endothelial cells, neovasculature fails to recruit the obligatory
perivascular cells including mural cells, and does not resemble
native, multilayered mature microvessels. Despite tremendous
progress, the field of angiogenesis is viewed as top priority in tissue
regeneration and tissue engineering, and also the area of least
progress in the past decade [16].
Bone marrow is populated by heterogeneous cell types including
end-lineage cells, committed tissue progenitors, and multipotent
stem/progenitor cells [17,18]. Two multipotent stem/progenitor
cells can be readily isolated from a single bone marrow aspirate:
mesenchymal stem/progenitor cells (MSCs) and hematopoietic
stem/progenitor cells (HSCs) [17,18]. Previous work has well
explored the regeneration of mesenchymal phenotypes such as
bone, adipose and cartilage tissues, by MSCs [19]. During
development, mesenchymal progenitor cells co-localize in hema-
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[20]. During endochondral bone development, invasion of the
primary ossification center artery precedes bone formation [21].
Hypertrophic chondrocytes express several critical transcriptional
factors and cytokines, including the pivotal vascular endothelial
growth factor (VEGF), and elaborate angiogenesis, which in turn
promotes bone formation [22]. During bone fracture healing,
some of the mobilized repair cells are vascular derived and migrate
into the fracture site to participate in the healing process [23–25].
The rate of fracture healing is related to angiogenesis [26,27]. For
instance, poor bone healing after irradiation is largely attributed to
a compromised vascular bed; conversely, enhancement of vascular
supply promotes the regeneration of irradiated bone [28].
Whereas it is logical to exploit the full potential of MSCs on bone
regeneration, suboptimal vascularization, a commonly recognized
barrier of bone tissue engineering, has not been addressed by
taking advantage of the capacity for neovascularization and
hematopoiesis by HSCs.
Recently, a great deal of interest has focused on the interactions
between HSCs and MSCs [29]. For example, HSCs promote
osteogenic differentiation of MSCs via niche-initiated pathways in
vitro [30]. The mechanism of this interplay between HSCs and
MSCs is believed to follow the expression of bone morphogenetic
protein 2 (BMP-2) and BMP-6. Conversely, osteoblasts facilitate
the mobilization of hematopoietic stem cells [31]. Interestingly,
peripheral blood CD34
+ cells differentiate into cells that express
osteogenic markers such as osteocalcin and may participate
directly in bone healing [32]. During early development, CD34
+
haemagioblasts have been manipulated for their potential to
differentiate into vascular progenitor cells [30]. However, little is
known whether co-transplantation of HSCs and MSCs regener-
ates vascularized tissues including bone. CD34
+ hematopoietic
and CD34
2 mesenchymal stem/progenitor cells are co-inhabi-
tants of bone marrow, but have rarely been applied in conjunction
to heal tissue defects. In the present study, we co-transplanted
bone marrow derived human MSCs and HSCs in the micropores
of 3D calcium phosphate (CP) scaffolds. Following the delivery of
MSCs to the micropores of CP scaffolds, HSC-seeded Matrigel
was infused into MSC-residing micropores. Four weeks after
ectopic implantation in immunodeficient mice, human HSC and
MSC co-seeded grafts yielded marked vascular number and
diameter, and increased human osteocalcin expression, in
comparison to MSC transplantation alone. We then observed
that VEGF stimulated HSCs to differentiate into endothelial-like
cells, which expressed von Willebrand factor and formed
intercellular tubular structures in vitro. We subsequently delivered
VEGF to MSC- and HSC-co-transplanted microporous CP
scaffolds in vivo. The average vessel number and diameter upon
VEGF delivery in MSC- and HSC-seeded microporous CP
scaffolds further increased. Due to their co-localization in bone
marrow and therefore isolation by a single aspiration procedure,
hematopoietic and mesenchymal stem/progenitor cells may be co-
transplanted, and improve the regeneration of vascular dependent
tissues such as bone, muscle, adipose, dermal, nerve grafts, and
may have implications in the regeneration of internal organs.
Materials and Methods
Isolation of hematopoietic and mesenchymal stem/
progenitor cells from the same human bone marrow
sample
Bone marrow cells were isolated from whole marrow aspirates
of the iliac crest of each of three healthy male donors (AllCells,
Berkeley, CA) and plated as in Fig. 1A. Human mesenchymal
stem cells (MSC) were isolated per our previous methods using
RosetteSep mesenchymal enrichment cocktail (StemCell Tech-
nologies, Vancouver, Canada) [33] (Fig. 1B) as mononucleated
and adherent cells. In a separate experiment, MSCs were found
not to express CD34 (data not shown). MSC were culture-
expanded in Dulbecco’s Modified Eagle’s Medium (DMEM-c;
Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Norcross, GA), and 1% antibiotic and
antimycotic (10,000 U/mL penicillin (base), 10,000 mg/mL strep-
tomycin (base), 25 mg/mL amphotericin B) (Atlanta Biologicals) at
37uC, 95% humidity, and 5% CO2 [34,35].
A subset of the whole marrow was used to isolate CD34
+ cells
using EasySep magnetic nanoparticles (StemCell Technologies,
Vancouver, Canada). The whole marrow was mixed with the
CD34
+ selection cocktail and magnetic nanoparticles per manufac-
turers protocol. Additional experiments also utilized commercially
available human bone marrow derived CD34
+ cells for verification
(AllCells, Berkeley, CA). The isolated CD34
+ cells (Fig. 1D)w e r e
removed from solution using a magnet (StemCell Technologies,
Vancouver, Canada) and culture-expanded in IMDM (Iscoves
Modified Dulbeccos Medium), supplemented with 20% FBS,
100 ng/mL SCF (stem cell factor), 100 ng/mL Flt-3 ligand,
20 ng/mL IL-3 (interleukin-3), and 20 ng/mL IL-6 in a non-tissue
culture treated dish. Note that fibroblast-likeMSCs (Fig. 1B) exhibit
drastically different morphology from HSCs (Fig. 1D)t h a ta r e
rounded and smaller, when both stem/progenitor cell types were
cultured in vitro. Isolated CD34
+ cells were culture expanded
(Fig. 1E) and a subset of these cells were differentiated into
endothelial-like cells, with details described below.
Osteogenic differentiation of mesenchymal stem cell-
seeded bone grafts
Culture expanded bone marrow-derived MSCs were detached
from culture plates using trypsin-EDTA and formed a 5610
6 cells/
mL suspension. Ethylene oxide gas sterilized 3D-calcium phosphate
(CP) scaffolds (BD Biosciences, Bedford, MA) were pre-wetted in
DMEM with 10% FBS, and submerged into MSC suspension in
polypropylene round bottom test tubes with snap-caps. Mineralized
CPscaffolds were non-compressible sponges with hydration capacity
of 30 mL, 60610 mm porosity, and 200–400 mm pore size. The
rationale for selecting CP scaffolds is primarily due to its widespread
use in bone regeneration. Tubes were snap-sealed and vacuum was
applied using a 20 ccsyringe and incubated at 37uCfor 3 hrs.MSC-
seeded 3D scaffolds were cultured overnight in expansion medium
and then transferred to osteogenic culture for 21 days consisting of
DMEM-c supplemented with 100 nM dexamethasone, 0.05 mM
ascorbic acid-2-phosphate and 10 mM b-glycerophosphate, per our
previous work [34–36,37]. Human MSCs cultured under osteogenic
condition underwent osteogenic differentiation and mineral depo-
sition Fig. 1C.
Co-transplantation of HSCs and MSCs
Culture expanded CD34
+ cells were suspended in Matrigel (BD
Biosciences) at a density of 1610
6 cells/mL. Microporous CP
scaffolds with MSCs seeded on pore surfaces were dried with
sterile gauze, immediately submerged in the CD34
+ cell suspended
gel and subjected to mild vacuum to induce infusion of cell/gel
suspension into the pores (200–400 mm) of the CP scaffold
(563m m
3; dia.6height) (Fig. 1F,1G). Scaffolds were maintained
in DMEM-c overnight prior to implantation. A total of four
groups were created: 1) MSC transplantation alone, 2) VEGF-
adsorbed MSC transplantation, 3) co-transplantation of MSCs
and CD34
+ cells, and 4) VEGF-adsorbed co-transplantation of
CD34+/2 Cells and Angiogenesis
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+ cells. Microporous CP scaffolds with cytokine-
free and cell-free Matrigel served as controls.
Ectopic implantation of tissue grafts in vivo
All tissue grafts, including controls, were implanted following
local IACUC approval. Nude mice were weighed and anesthetized
with 3% isoflurane inhalation in an induction chamber, with
anesthesia maintained with a nose cone (isoflurane 1–3%). A
2 cm-long linear incision was made along the midsagittal line of
the dorsum. Tissue grafts were implanted in the subcutaneous
pocket superior to dorsal muscles (Fig. 1H). All grafts were
harvested after 4 wks by removing the fibrous capsule, and cut into
two halves. One half was lysed in 16triton-X solution, crushed,
sonicated on ice for 20 s, and stored at 220uC until further
analysis for ELISA, etc. The second half was fixed in 10%
formalin and either embedded in GMA or paraffin for histological
and immunohistochemical analyses as described below.
Histology, immunohistochemistry, histomorphometry,
and biochemical analyses
Specimens were demineralized in equal volumes of 20% sodium
citrate and 50% formic acid, subsequently embedded in paraffin,
sectioned in the transverse plane at 5 mm thickness and stained with
hematoxylin and eosin (H&E) or Massons Trichrome stain
[35,39,41]. Undemineralized specimens were embedded in GMA,
sectioned at 20 mm and stained with H&E [42]. Sequential sections
were immunostained for human osteocalcin (Cambridge, MA) and
human nuclei (Millipore, Billerica, MA) for visualizing the extent of
osteogenesis and the contribution of transplanted cell to neovascu-
larization, respectively. Computerized histomorphometric analysis
was performed to quantify blood vessel number and blood vessel
diameter using grid analysis [43]. All biochemical assays were
evaluated using thawed, lysed samples. DNA content was determined
using fluorescent DNA quantification kit (BioRad Labs, Hercules,
CA) and expressed as ng DNA per mL of sample. Osteocalcin was
detected using a human osteocalcin ELISA kit (R&D Systems,
Minneapolis, MN) and von Willebrand factor (vWF) using human
vWF-specific ELISA (Helena Laboratories, Beaumont, TX).
Endothelial differentiation of hematopoietic stem/
progenitor cells in vitro
Culture expanded HSCs were induced to differentiate into
endothelial-like cells by plating onto fibronectin coated plates with
endothelial differentiation medium containing IMDM supple-
mented with 10% FBS, 1% Antibiotics/Antimycotics, 10 ng/mL
VEGF (vascular endothelial growth factor), 1 ng/mL bFGF (basic
fibroblast growth factor), and 2 ng/mL IGF-1 (insulin-like growth
factor-1).
Statistical analysis. ANOVA and post-hoc Bonfferroni tests
were used to compare all quantitative data between the control
group and each experimental group at an a level of 0.05.
Results
In vivo vascularization of tissue grafts generated from
CD34
+ hematopoietic stem/progenitor cells and CD34
2
mesenchymal stem/progenitor cells
Microporous, 3D calcium phosphate scaffolds co-transplanted
with HSCs and mesenchymal stem/progenitor cells implanted
subcutaneously in the dorsum of athymic nude mice were
evaluated for both angiogenesis and osteogenesis. Four weeks
after in vivo implantation, bone grafts with co-transplanted HSCs
and MSCs demonstrated notably visible vascular ingrowth into the
micropores of CP scaffolds (black arrows in Fig. 2B1, B2). In
comparison, only limited vascular ingrowth was observed in MSC
transplantation alone (Fig. 2A1, A2). Neovascularization was
apparently anastomosed with host vasculature, given the presence
of red blood cells within vessel walls formed by endothelial cells.
Endothelial differentiation of hematopoietic stem/
progenitor cells
We further examined whether CD34+ cells isolated in the
present study can be differentiated into endothelial progenitor cells
or endothelial cells by VEGF, a growth factor with potency on
endothelial differentiation [15]. We first isolated CD34
+ cells from
donated human bone marrow samples by positive selection
(Fig. 3A). When grown in suspension culture, CD34
+ cells
remained spherical and non-attached (Fig. 3A). Upon seeding on
fibronectin-coated plates in endothelial differentiation medium
including VEGF, CD34
+ cells attached to the plate and formed
colonies (Fig. 3B). When seeded on 3D Matrigel and exposed to
endothelial differentiation medium, CD34
+ cells formed intercon-
necting tubular networks that are reminiscent of early angiogenesis
and characteristic of endothelial progenitor cells (Fig. 3C).
Endothelially differentiated CD34
+ cells on fibronectin-coated
plates showed positive immunofluorescent staining for acetylated
LDLs (Fig. 3D) and von Willebrand factor (vWF) (Fig. 3E), both
typical for endothelial progenitor cells. Quantitatively, endotheli-
ally differentiated CD34
+ cells (HSC-ECs) expressed substantial
vWF normalized to DNA content, in comparison to dermal
fibroblasts that were used as controls (Fig. 3F).
Enhanced angiogenesis of VEGF-stimulated, co-
transplanted HSC and MSC co-seeded grafts in vivo
Four weeks after in vivo implantation, bone grafts with VEGF-
stimulated, co-transplanted HSCs and MSCs showed substantial
vascular ingrowth into the micropores of CP scaffolds (Fig. 4A,
4B). In comparison with VEGF-delivered MSC transplantation
alone (Fig. 4C, 4D) or co-transplanted HSCs and MSCs but
without VEGF delivery (Fig. 2B1, 2B2), VEGF-stimulated HSC
and MSC co-transplantation yielded not only more, but also larger
blood vessels that were populated by red blood cells and lined by
endothelial cells (Fig. 4A, 4B). This is especially true when
Figure 1. Isolation of hematopoietic stem/progenitor cells and mesenchymal stem/progenitor cells from a single bone marrow
aspiration. A. Human bone marrow is aspirated from the iliac crest of donor patients. B. Mesenchymal stem/progenitor cells (MSC) isolated from
human bone marrow attach to tissue culture plates and assume typical spindle, fibroblast-like shape. C. Von Kossa stained MSC-derived osteoblasts
in osteogenic differentiation medium. Black stained mineralized nodules are observed as well as pericellular staining throughout the plate. D.
Hematopoietic stem/progenitor cells (HSCs) are isolated from the same human bone marrow sample. E. HSCs are expanded in suspension culture,
smaller than MSCs, and non-adherent, in addition to maintaining spherical shape. F. MSCs are seeded on the surfaces of the micropores of the 3D
cylindrical calcium phosphate (CP) scaffold. Culture expanded HSCs with or without VEGF are then seeded in Matrigel and infused into the
micropores of the 3D CP scaffolds to complete implant fabrication (controls included Matrigel with no HSCs, or with VEGF alone). G.
Carboxyfluoroscein diacetate (CFDA) labeled MSC and HSCs labeled with red CM-DiI are visualized in the micropores of the 3D graft. Green MSC are
on the surface of the micropores of the CP scaffold, whereas red HSCs are suspended in Matrigel that is infused into MSC-occupied pore surface. H.
Scaffolds are implanted subcutaneously in the dorsum of immunocompromized mice.
doi:10.1371/journal.pone.0003922.g001
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with previous findings that VEGF delivery alone fails to elaborate
mature blood vessels [44,45]. Quantitatively, the average number
of blood vessels markedly increased for VEGF-stimulated co-
transplantation of HSCs and MSCs, in comparison with MSC
transplantation alone, VEGF delivery alone and co-transplanta-
tion of HSCs and MSCs but without VEGF delivery (Fig. 4E).
VEGF delivery with HSC and MSC co-transplantation yielded an
,240% increase in vessel number over MSC transplantation
group (p,0.05) (Fig. 4E). VEGF delivery along with co-
transplantation of HSCs and MSCs also yielded large blood
vessels, in comparison with MSC transplantation alone, VEGF
delivery alone or co-transplantation of HSCs and MSCs but
without VEGF (Fig. 4F).
Contribution of transplanted human HSCs and MSCs to
endothelium
Transplanted HSCs and MSCs were engrafted into the
endothelium of host-derived blood vessels. Upon immunohisto-
chemical visualization of human-specific nuclear antibody,
transplanted human HSCs and MSCs were found broadly in
tissue grafts and in some cases, formed vascular endothelium with
or without VEGF delivery (red arrows in Fig. 5C,5D). Engraft-
ment of transplanted human cells and co-localized host (mouse)
cells participated in the formation of endothelium (Fig. 5C,5D).
Red blood cells populated blood vessel lumen (L in Fig. 5C,5D)
that was lined by human-host (mouse) derived endothelium,
suggesting that blood vessels in tissue grafts anastomosed with host
vasculature. In contrast, blood vessels formed by MSC transplan-
tation alone with or without VEGF, but in the absence of
transplanted HSCs, had broad engraftment of human cells, but
rarely within the endothelium (Fig. 5A, 5B).
Ectopic mineralization in vascularized grafts generated
from CD34
+ and mesenchymal stem/progenitor cells
Ectopic mineral apposition was observed in the micropores of
the CP grafts. Massons Trichrome staining showed areas of
collagen fiber accumulation within the micropores of the CP
scaffold (Fig. 6). While MSC transplantation with or without
VEGF delivery resulted in mild areas of Masson’s trichrome
staining (Fig. 6A1, A2 and Fig. 6B1, B2), moderate collagen
apposition was found in association with co-transplanted HSCs
and MSCs but without VEGF (Fig. 6C1, C2). Importantly,
substantial Masson’s trichrome staining was present along the
interface of tissue formation and microporous CP scaffolds
(Fig. 6D1). High magnification of VEGF-delivered, HSC and
MSC co-transplantation sample showed robust collagen deposi-
tion and areas of apparent bone trabecula-like structures
(Fig. 6D2). Immunohistochemical analysis showed the presence
of human-specific osteocalcin in the micropores of CP scaffolds
implanted subcutaneously in SCID mice (Fig. 7A–E), indicating
that transplanted human cells synthesized osteocalcin. Isolated
areas of human-specific osteocalcin staining were found in MSC
transplantation with or without VEGF delivery (Fig. 7A,B). In
contrast, representative samples of co-transplantation of MSCs
and HSCs with or without VEGF showed substantial areas of
human-specific osteocalcin staining (Fig. 7C,D). Osteoblast-like
cells are observed on the surface of calcium phosphate scaffolds
(CP) (black arrow in Fig. 7D). Quantitatively, the expression of
human-specific osteocalcin was significantly more robust upon co-
transplantation of MSCs and HSCs, interestingly, without VEGF
delivery, than MSC transplantation alone, presenting an ,220%
increase (p,0.05) (Fig. 7E). Mineral apposition is verified on
undecalcified sections (yellow arrows in Fig. 7F–I). Isolated brown
areas at the interface of newly formed tissue and CP scaffold were
Figure 2. Vascularization of in vivo implanted tissue grafts. H&E staining. A. Microporous calcium phosphate (CP) scaffolds seeded with
mesenchymal stem/progenitor cells (MSCs) alone showed minimal vascularization of the micropores of the implant. B. Co-transplantation of
hematopoietic stem/progenitor cells (HSCs) and MSCs resulted in substantial numbers of blood vessels (black arrows) in the micropores of the CP
scaffolds.
doi:10.1371/journal.pone.0003922.g002
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(Fig. 7F,G). In contrast, extensive brown areas were present in the
co-transplantation sample seeded with HSCs and MSCs (yellow
arrows in Fig. 7H). Similarly, the representative sample of co-
transplantation of HSCs and MSCs with VEGF delivery also
showed extensive areas of mineral apposition (yellow arrows in
Fig. 7I).
Discussion
The present results constitute an original discovery that tissue
vascularization and regeneration is enhanced by co-transplanta-
tion of mesenchymal stem/progenitor cells and hematopoietic
stem/progenitor cells. Given that HSCs and MSCs can be readily
isolated from a single bone marrow aspiration procedure [46–48],
Figure 3. Endothelial differentiation of HSCs in vitro.A .Hematopoietic stem/progenitor cells (HSCs) propagated in suspension culture,
assuming spherical shape. B. HSCs form endothelial-like colonies in fibronectin-coated plates. C. Formation of tubular intercellular structures in 3D
Matrigel culture. Uptake of acetylated-LDLs (red) (blue: DAPI) (D) and vWF (von Willebrand Factor) immunofluorescent stain (green) (E). F.
Quantification of vWF measured by ELISA showing substantial expression of vWF in HSC-derived endothelial-like cells, in comparison with dermal
fibroblasts as controls.
doi:10.1371/journal.pone.0003922.g003
CD34+/2 Cells and Angiogenesis
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3922Figure 4. VEGF enhances neovascularization of HSC and MSC co-transplanted scaffolds. A. VEGF delivered with transplanted HSCs
promoted increased neovascularization of large diameter, indicative of increasingly mature blood vessels. Red blood cells are observed in
neovasculature indicating anastomosis to host and functionality (A–D:H&E stain). B. Higher magnification of A. C. VEGF delivered MSC
CD34+/2 Cells and Angiogenesis
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to combine the delivery of HSCs and MSCs towards generating
vascularized tissues. Given that suboptimal angiogenesis is the
common roadblock in tissue regeneration, the present co-
transplantation of HSCs and MSCs offers an alternative to other
angiogenic approaches that have been previously investigated,
such as delivery of growth factors or the fabrication of blood vessel
analogs [3–6]. MSCs and HSCs have rarely been delivered in
combination for the healing of defects or the treatment of diseases,
partially due to separate communities in which HSCs and MSCs
are studied. If the present approach is extendable to the promotion
of vascularization of other tissues such as adipose, cardiac,
muscular, nerve and dermal grafts, then a single bone marrow
aspirate may provide threshold numbers of expandable multi/
pluri-potent stem/progenitor cells including MSCs and HSCs for
vascularized tissue regeneration [37,38,40,49–52]. An additional
advantage of combined delivery of HSCs and MSCs appears to be
the disadvantages in association with the cost of multiple
angiogenic growth factors, transplantation of endothelial cells that
are difficult to isolate from patients and difficult to expand in vitro,
and challenges associated with microsurgery for connecting
bioengineered blood vessels.
The clear advantage of increased vascular number and vascular
diameter by co-transplantation of MSCs and HSCs, over MSC
transplantation alone, appears to indicate several putative
pathways via which HSCs may participate in synergistic actions
with MSCs. First, transplanted HSCs in the present work
differentiate into endothelial cells in vitro, and engraft into host-
derived vasculature in vivo. These findings suggest that HSCs not
only possess the critical signaling potential during tissue repair, but
also may directly participate as repair cells. HSCs may
differentiate into various hematopoietic elements, and anastomose
Figure 5. Transplanted human HSCs and MSCs engraft in vivo and into vascular endothelium of host vasculature. Immunostaining
(brown) of human specific nuclei of tissue grafts by MSC transplantation alone (without HSCs) (A), MSC transplantation with exogenous VEGF (B), co-
transplantation of MSCs and HSCs without VEGF delivery (C), or co-transplantation of MSCs and HSCs with VEGF delivery (D). Red arrows point to
human nuclei that engraft to forming blood vessel wall surrounding functional lumen (L) filled with red blood cells.
doi:10.1371/journal.pone.0003922.g005
transplantation group (no transplanted HSCs) fails to show substantial neovascularization as demonstrated by few sparse and small blood vessels. D.
High magnification of C. CP: calcium phosphate. E. Quantification of the average number of vessels showing significantly increased vasculature in
VEGF-stimulated HSC and MSC co-transplantation group (n=5, p,0.05). F. Histogram presentation of the average vessel diameters show that VEGF
delivery resulted in larger, and likely more mature, blood vessels towards the right tail of the histogram.
doi:10.1371/journal.pone.0003922.g004
CD34+/2 Cells and Angiogenesis
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human cells in vascular endothelium suggests that vascular
signaling by transplanted human cells promotes anastomosis with
host vasculature.Additional studies can be designed to separately tag
HSCs and MSCs, so to appreciate the relative contribution of both
cell types to the neovasculature. Second, MSCs and HSCs may act
as each other’s supportive cells, and reciprocally promote tissue-
forming and vascular support functions. This speculation is clearly
beyond the scope of the present study, but warrants separate studies.
Third, we are somewhat surprised that MSC transplantation alone
in the present work yields somewhat disappointing regeneration as
well poor angiogenesis. This may be attributed to a modest number
of MSCs and partial differentiation of MSCs into osteogenic cells.
Also, our data do not rule out a possibility that MSCs have
differentiated into endothelial-like cells in vivo in the present model,
as shown before [53–55]. Human nuclei staining does demonstrate
engraftment of the transplanted human cells in regenerating tissue in
the pores of CPscaffold,but few transplantedMSCs arefoundinthe
vascular wall unless HSCs are co-transplanted. Follow up studies are
warranted to determine to what extent MSCs differentiate into
endothelial cells in vivo.
Vascular endothelial growth factor (VEGF) is used in the
present work along with co-transplantation of HSCs and MSCs,
and further enhances vascular number and vascular diameter. In
the present complex system, VEGF’s actions are likely multi-
dimensional. VEGF clearly promotes the differentiation of HSCs
towards endothelial progenitor cells or endothelial cells in vitro as
shown in the present work, but may have also concomitantly
signaled and recruited host-derived vascular network in vivo [56].
VEGF and other angiopoietins mobilize and activate hematopoi-
etic cells, and may provide obligatory signaling for the differen-
tiation and stabilization of endothelial cells [57,58]. Differentiated
endothelial cells express abundant VEGF receptors, but secrete
little VEGF [59], whereas VEGF stimulates autocrine pathways of
HSCs and promotes cell survival [60]. Thus, the present approach
to co-transplant HSCs and MSCs may maximize the potential of
transplanted multi-lineage cells, and allow them to be activated by
local cues of the injured tissue. The present VEGF delivery via
diffusion from a scaffold gel will lead to its rapid release, consistent
with previous work advocating that VEGF should be delivered
early in regeneration [7]. During native angiogenesis, VEGF
expression peaks early, followed by other angiopoietins such as
PDGF (platelet derived growth factor) [7]. Given that HSCs are
progenitors of platelets, we speculate that the transplanted CD34
+
cells may directly differentiate into or mediate the differentiation of
platelets which are important for vessel wall maturation and the
recruitment of mural cells [61].
An interesting observation of our data is that VEGF delivery is
accompanied by a decline of human osteocalcin content. This is
likely attributed to several factors. A fraction of CD34
+ cells have
beenshowntoexpressosteocalcinandtoengraft inhealingfractures
[62–64]. Also, a percentage of osteocalcin and alkaline phosphatase
expressing cells from peripheral blood with osteogenic potential are
CD34 positive [65]. In the present work, CD34
+ cells may have
participated in mineral apposition and the expression of human
osteocalcin. Conversely, delivery of VEGF in the present work may
have promoted endothelial differentiation of the transplanted
CD34
+ cells; accordingly, fewer CD34
+ cells engage in osteocalcin
synthesis. Additional studies are designed to explore the effects of
VEGF dosing on HSCs and MSCs. Together, the present co-
transplantation of hematopoietic and mesenchymal stem/progen-
itor cells yields vascularized tissue regeneration. Vessel number and
diameter that are elaborated by HSCs and MSCs are found to
further improve upon VEGF delivery. These original findings are
perhaps reminiscent of the native development process as well
characterized in bone development. Prior to the arrival of primary
ossification center artery, diaphyseal bone fails to develop. Although
the oxygenation and diffusion properties of the engineered bone are
not outcome measures of the present study, we suspect that the
present approach may have induced angiogenesis and vasculogen-
esis both from outside in (host-derived) and inside out (human cell
driven). Given the approximate 100–200 mm limitation for vascular
supply in native tissue, it would be of interest to determine whether
oxygenation and diffusion properties of engineered bone, such as
Figure 6. Collagen apposition in tissue grafts in vivo. A–D. Masson’s trichrome staining (blue) shows increased pre-mineralizing collagen
deposition and osteoid formation in co-transplantation of MSCs and HSCs without VEGF (C1) and VEGF-delivered MSC and HSC co-transplantation
sample (D1), in contrast to MSC transplantation alone (A1) and VEGF-delivered MSC transplantation sample (B1). A2–D-2. Magnification of red
boxes in A1–D1, respectively.
doi:10.1371/journal.pone.0003922.g006
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approach likely filters out some end lineage cells from bone marrow
aspiration and provide an initial selection of HSC and MSC
populations. Therefore, this approach differs from whole marrow
transplantation with or without further processing. Taken together,
synergistic actions of hematopoietic and mesenchymal stem/
progenitor cells may provide an alternative approach for the
regeneration of vascular tissues such as bone, adipose, cardiac,
muscle and dermal grafts.
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